REG - Spire Healthcare Grp - Director/PDMR Shareholding

Spire HealthcareAnnouncement

28/03/2025 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250328:nRSb7452Ca&default-theme=true

RNS Number : 7452C  Spire Healthcare Group PLC  28 March 2025

Spire Healthcare Group plc (the Company)

28 March 2025

 

Notification of Transactions of Persons Discharging Managerial
Responsibilities

 

Grant of Long Term Incentive Plan (LTIP) awards

The Company announces that, on 27 March 2025, a performance share award was
granted over the Company's ordinary shares in the form of nil cost options to
the following Executive Directors in the Company, under the rules of the
Company's Long Term Incentive Plan.

 

Executive Director                Maximum number of shares
under Award

Justin Ash                               759,173

Harbant Samra                       436,681

 

The number of shares set out above represents 200% of current base salary.
It is the maximum number which may vest under the LTIP Awards following the
end of the performance period (31 December 2027).  The shareholder-approved
Remuneration Policy permits awards of up to 200% of base salary for Executive
Directors.

 

The actual number of shares which vest will depend on the extent to which the
relevant performance conditions have been satisfied.

 

The performance conditions applicable to the LTIP Awards will be based as
follows:

·    20% on relative total shareholder return (TSR) performance;

·    35% on ROCE performance;

·    15% on Hospital EBIT Margin performance; and

·    30% on two Operational Excellence measures.

 

Further details of these performance conditions will be disclosed in the 2024
Annual Report and Accounts when published.

 

The share price used to determine the number of shares under the LTIP Awards
was 174.04 pence being the average of the mid-market closing share price over
the five trading days ending on 26 March 2025.

 

The transaction place is London.

 

Notes:

 

1)   For both Executive Directors the 2025 LTIP awards described above will
also be subject to a further two-year holding period following the vesting
date.

2)   The actual number of shares which vest under the LTIP awards will
depend on the extent to which the relevant performance conditions are
satisfied in due course.

Name of contact and telephone number for queries:

Philip Davies

Head of Secretariat

Spire Healthcare Group plc

Tel:      07803 508348

 

 

Notification and public disclosure of transaction by persons discharging
managerial responsibility and persons closely associated with them

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Justin Ash

 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer/PDMR

 b)  Initial notification /Amendment                              Initial notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Spire Healthcare Group plc

 b)  LEI                                                          213800IBJPW3SE2RA350

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

     Identification code

                                                                  GB00BNLPYF73
 b)  Nature of the transaction                                    Grant of performance share awards under the Company's Long Term Incentive Plan
 c)  Price(s) and volume(s)                                       Price(s)                                  Volume(s)
                                                                  Nil                                       759,173

 d)  Aggregated information                                       As above

     - Aggregated volume

     - Price
 e)  Date of the transaction                                      2025-03-27
 f)  Place of the transaction                                     XLON

 

 a)  Name                                                         Harbant Samra

 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer

 b)  Initial notification /Amendment                              Initial notification

 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Spire Healthcare Group plc

 b)  LEI                                                          213800IBJPW3SE2RA350

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

     Identification code

                                                                  GB00BNLPYF73
 b)  Nature of the transaction                                    Grant of performance share awards under the Company's Long Term Incentive Plan
 c)  Price(s) and volume(s)                                       Price(s)                                  Volume(s)
                                                                  Nil                                       436,681

 d)  Aggregated information                                       As above

     - Aggregated volume

     - Price
 e)  Date of the transaction                                      2025-03-27
 f)  Place of the transaction                                     XLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBXGDXIGDDGUI